1 / 26

6660: Whole-Body MRI in the Evaluation of Pediatric Malignancies

This study aims to establish non-inferior diagnostic accuracy of whole-body MRI compared to conventional imaging for detecting metastatic disease in common pediatric tumors.

Download Presentation

6660: Whole-Body MRI in the Evaluation of Pediatric Malignancies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 6660: Whole-Body MRI in the Evaluation of Pediatric Malignancies Marilyn J. Siegel, MD (Principle Investigator) Fredric Hoffer, MD Suddhasatta Acharyya, PhD Brad Wyly, MD Berry Siegel, MD Alison Friedmann, MD, MSc

  2. Biostatisticians: Brad Snyder, MS & Vincent Girardi, MS Lead Data Manager: Jamie Downs ACRIN 6660: Whole-Body MRI in the Evaluation of Pediatric Malignancies

  3. Establish non-inferior diagnostic accuracy of whole body MRI compared with conventional imaging studies for detecting metastatic disease for use in staging of common pediatric tumors 6660: Primary Aim

  4. Patients to undergo conventional studies including: Scintigraphy (Bone, MIBG or gallium) Abdominal/Pelvic CT or MRI Chest CT (optional for neuroblastoma) FDG-PET (optional) Experimental Studies Whole-Body Fast MRI ACRIN 6660: Study Overview

  5. Male or female gender 21 years or younger Suspected soft tissue sarcoma, Ewing’s sarcoma family of tumors, neuroblastoma, Hodgkin’s disease, and non-Hodgkin’s lymphoma. Initial imaging completed in a timely fashion Final analysis only included above proven tumor types Inclusion Criteria

  6. 192 patients enrolled 140 evaluable 51 with distant disease (or stage IV) 89 with lesser stage 70 selected for multi-reader study (35 with stage 4 solid tumor or advanced stage lymphoma) 21 FDG PET’s were included in conventional imaging of the reader study Materials

  7. Whole Body Imaging Vertex to toes Coronal plane images Body Coil Scans performed on a 1.5 T STIR Fast WBMRI Techniques

  8. STIR MR-Ewing Sarcoma

  9. Rhabdomyosarcoma MRI CT Mass Mass Renal Metastasis

  10. 10 readers for pretreatment conventional CT/MRI, experimental WBMRI 10 readers for pretreatment scintigraphy FDG-PET, bone scans, MIBG Readers initially blinded to & had washout period between conventional & experimental imaging 10 pairs of readers of conventional scintigraphy & cross sectional imaging had combined reports All pretreatment studies assessed for distant tumor extent Central Image Interpretation

  11. 4 oncologists, 1 pediatric radiologist Conventional imaging findings from primary readers Bone marrow biopsy CSF aspirates when available Additional confirmatory imaging Additional confirmatory biopsy 6 months of data to determine initial stage Proof of truth committee determined distant disease (usually stage 4)

  12. Reader study: accuracy as area under ROC curve (AUC) Average AUC whole-body MRI (WBMRI) vs. average AUC conventional imaging To declare non-inferiority of WBMRI vs. conventional imaging for detecting distant disease, the expected 95% lower bound of the confidence interval for AUC (WBMRI minus conventional imaging) must be above –0.03 (closer to zero) Determining the Primary Aim

  13. 70 cases (35-, 35+) WBMRI 0.8291 empirical, 0.8436 parametric Conventional imaging 0.8676 empirical, 0.8896 parametric AUC for ROC analysis

  14. The difference in AUC between the modalities [The 95% confidence interval (CI)] for WBMRI – Conventional Imaging = -0.0384 [-0.1091, 0.0323] empirically -0.0461 [-0.1195, 0.0274] parametrically The lower bound CI was not above -0.03 WBMRI could not be declared non-inferior to conventional imaging Results for primary aim

  15. WBMRI reader experience Lymphoma vs. other tumors Sensitivity Specificity Patient age Distant tumor size & locations Search for reasons that WBMRI failed to achieve non-inferiority

  16. WBMRI Reader experience: Empirical AUC • The experienced MRI readers did better on both WBMRI and conventional imaging readings.

  17. AUC as per tumor type There was a trend toward non-inferiority for WBMRI to detect stage 4 solid tumors but the sample size was not sufficient for statistical significance.

  18. Average sensitivity The average sensitivity for advanced stage lymphoma was lower than stage 4 solid tumors for both WBMRI & conventional imaging (p<0.0001).

  19. Average specificity • Average specificity of WBMRI tended to be better than conventional imaging for solid tumors but not significantly

  20. Age of patient vs. WBMRI reading • This trend failed to suggested that the red marrow of patients under age 2 was confused with bone marrow tumor on WBMRI.

  21. Weighted averages of false negatives (FN) for WBMRI reading (all missed lesions were <1 cm)

  22. False negative (FN) cases missed by >5 of 10 readers by WBMRI or conventional imaging among 35 positive cases

  23. False negative (FN) WBMRI & conventional readings in a subset of 13 of 35 + cases missed by >5 readers

  24. ACRIN 6660 failed to demonstrate that WBMRI with STIR coronal imaging is not inferior to conventional imaging for determining metastatic pediatric malignancy • WBMRI had more false negatives than conventional imaging due to lung metastases & other lesions < 1 cm • WBMRI trended to be as accurate & more specific than conventional imaging for determining solid tumor metastases (but not for advanced lymphoma) Conclusion

  25. Image Gently • www.imagegently.org • CT is the major source of radiation in diagnostic radiology • Children are more susceptible than adults to cancer after radiation exposure

  26. Whole-body diffusion-weighted imaging for staging malignant lymphoma in children. Kwee TC, Takahara T, Vermoolen MA, Bierings MB, Mali WP, Nievelstein RA. Pediatr Radiol. 2010 Oct;40(10):1592-602. Whole-body MR imaging, bone diffusion imaging: how and why? Jaramillo D. Pediatr Radiol. 2010 Jun;40(6):978-84. Diffusion weighted Whole Body MRI

More Related